A clinical trial where 120 participants will wear one of three contact lenses (SEED Pure, CooperVision Proclear or Johnson & Johnson Vita), for three months with monthly replacement to determine clinical performance.

Not Applicable

Completed

• Conditions: Myopia; Eye - Diseases / disorders of the eye

• Registration Number: ACTRN12618000039280
• Lead Sponsor: Brien Holden Vision Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-01-12
• Study Completion: 2018-09-14
• Last Update Posted: 26 November 2018

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 124

Inclusion Criteria

Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent.
Be at least 18 years old, male or female.
Willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator.
Have ocular health findings considered to be normal” and which would not prevent the participant from safely wearing contact lenses.
Is correctable to at least 6/7.5 (20/25) or better in each eye with best-corrected subjective refraction and 6/12 (20/40) or better in each eye with contact lenses.
Can be an experienced or first time (neophyte) contact lens wearer.
Be able to insert and remove contact lenses.

Exclusion Criteria

Any pre-existing ocular irritation, injury or condition (including infection or disease) of the cornea, conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses.
Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjogrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants.
Use of or a need for concurrent category S3 and above ocular medication at enrolment and/or during the clinical trial.
Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant’s ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial.
NB: Systemic antihistamines are allowed on an as needed basis”, provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used.
Eye surgery within 12 weeks immediately prior to enrolment for this trial.
Previous corneal refractive surgery.
Contraindications to contact lens wear.
Known allergy or intolerance to ingredients in any of the clinical trial products.
Currently enrolled in another clinical trial.
Participation in a clinical trial within the previous 2 weeks for dispensing studies and 48 hours between in-house studies.
Pregnancy*.
The Investigator may, at his/her discretion, exclude anyone who they believe may not be able to fulfil the clinical trial requirements or it is believed to be in the participant’s best interests.
*Formal testing of pregnancy is not required. A participant’s verbal report is sufficient.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Subjective rating of comfort with contact lenses as assessed with a questionnaire utilising numeric rating scales (1-10 in 1-point steps) .[Baseline, 2 weeks, 1 month, 2 months, 3 months];Subjective rating of clarity of vision with contact lenses as assessed with a questionnaire utilising numeric rating scales (1-10 in 1-point steps) .[Baseline, 2 weeks, 1 month, 2 months, 3 months];Subjective rating of lens handling with contact lenses as assessed with a questionnaire utilising numeric rating scales (1-10 in 1-point steps).[Baseline, 2 weeks, 1 month, 2 months, 3 months]